Humanized Anti-IL-5 Antibody Therapy

Marc E Rothenberg1

  • 1Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA.

Cell
|April 23, 2016
PubMed

Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years.

Related Concept Videos